Dedicated to finding new medicines for a variety of diseases by targeting the ubiquitin pathway, a critical mechanism of cellular regulation. Using our UbiPro™ Discovery Platform we have identified selective inhibitors of critical ubiquitin pathway enzymes associated with cardiovascular disease, cancer and other debilitating diseases. This technology and multiple selective compounds are available for licensing.
Progenra’s goal is to discover novel drugs targeting the ubiquitin pathway using their proprietary technology.
E3 LIGASE TECHNOLOGY
Progenra is seeking industry partnerships for licensing opportunities surrounding the company’s small molecule portfolio and/or its proprietary UbiPro™ Drug Discovery Platform.
Progenra, Inc. has been awarded a composition of matter patent covering their first series of small molecule USP7 inhibitors. The highly conserved ubiquitin pathway plays an important role in the regulation of cellular activity and prior work by Progenra and others has identified the deubiquitylating enzyme USP7 as a key regulator of this pathway. Dysregulated USP7 activity has been implicated in cancer, inflammation and other diseases. The issued patent, entitled “Anti-neoplastic compounds, compositions and methods” (US 8,680,139), covers the small molecule USP7 inhibitor P0005091 and related structures.